Search results for "TUMORS"

showing 10 items of 1138 documents

Mitotane Concentrations Influence Outcome in Patients With Advanced Adrenocortical Carcinoma

2020

Mitotane is the main option of treatment for advanced adrenocortical carcinoma (ACC). However, limited evidence is available regarding the impact of plasma mitotane levels on patient outcome. To address this question, we retrospectively analyzed patients with advanced ACC treated with mitotane for &ge

OncologymitotaneCancer Researchmedicine.medical_specialtyMultivariate analysisrecurrenceCombination therapyPrognosimedicine.medical_treatment030209 endocrinology & metabolismDiseaselcsh:RC254-282behavioral disciplines and activitiessurvivalArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdrenocortical carcinomaMitotaneIn patientadrenal cancerObjective responseadrenal cancer; mitotane; prognosis; recurrence; survivalChemotherapybusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseOncology030220 oncology & carcinogenesisprognosisbusinessAdrenal cancer Mitotane Prognosis Recurrence Survivalmedicine.drug
researchProduct

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy

2021

Valentina Burgio,1 Massimo Iavarone,2 Giovanni Giuseppe Di Costanzo,3 Fabio Marra,4 Sara Lonardi,5,6 Emiliano Tamburini,7 Fabio Piscaglia,8 Gianluca Masi,9,10 Ciro Celsa,11 Francesco Giuseppe Foschi,12 Marianna Silletta,13 Daniela Caterina Amoruso,14 Margherita Rimini,15 Mariangela Bruccoleri,2 Raffaella Tortora,3 Claudia Campani,4 Caterina Soldà,6 Massimo Giuseppe Viola,16 Antonella Forgione,8 Fabio Conti,12 Francesca Salani,9,10 Silvia Catanese,9,10 Carmelo Marco Giacchetto,17 Claudia Fulgenzi,13 Carmine Coppola,14 Pietro Lampertico,18 Antonio Pellino,6,19 Gabriele Rancatore,17 Giuseppe Cabibbo,17 Francesca Ratti,20 Federica Pedica,21 Angelo Della Corte,22 Massimo Colombo,18 Francesco De…

Oncologysorafenib.Cancer Management and ResearchhepatocarcinomaNeoplasms. Tumors. Oncology. Including cancer and carcinogenssorafeniblenvatinibneoplasmsdigestive system diseasesRC254-282Original ResearchCancer Management and Research
researchProduct

Breast Cancer Diagnosis in Coronavirus-Era: Alert From Italy

2020

OpinionCancer Research2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)business.industrydiagnosisSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)screeningCOVID-19medicine.diseasemedicine.disease_causelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensVirologylcsh:RC254-282Breast cancerbreast cancerOncologyItalymedicinebusinessCoronavirusFrontiers in Oncology
researchProduct

Gigantic tongue lipoma : a case report

2006

Lipomas are among the most common tumors of the human body. However, they are uncommon in the oral cavity. In the oral cavity they present as a slow growing, painless, and assymptomatic yellowish submucosal mass. Surgical excision is the treatment of choice with recurrence not expected. They have been known to grow to large sizes causing mastication and speech difficulties. The usual lesions consist of a well circumscribed, lobulated mass of mature fat cells. In other situations the covering mucosa becomes ulcerated and presents difficulties in diagnosis. The present report is of a patient who presented with a gigantic lipoma on the tip of the tongue which had been present for 3 years. She …

Oral lipomalingual tumorstomatognathic diseasesoral tumorsUNESCO::CIENCIAS MÉDICASotorhinolaryngologic diseaseslingual lipoma:CIENCIAS MÉDICAS [UNESCO]
researchProduct

Surgical Treatment on Subungual Osteochondromas in Paediatric Feet: A Case Series Study

2020

Subungual osteochondroma (SO) is an infrequent and non-malignant bone tumour of the distal phalanx, especially prominent in paediatric populations. The aim of this research was to describe a case series of paediatric feet with SO which received surgical treatments. The secondary purpose was to compare these descriptive data by sex distribution. Methods: Twenty-three paediatric feet with SO confirmed by clinical or radiological features received surgical treatment. Socio-demographic (age, sex, height, weight and BMI) and clinical features (side, location, tumour or pain presence, and nail lift before surgery, as well as recurrence and adverse effects at one month after intervention) were rep…

Osteochondromamedicine.medical_specialtyQuistesbone tumourlcsh:MedicineFisiología humanaArticlelaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialchildrenlawmedicine030212 general & internal medicineOssos MalaltiesSistema musculoesqueléticoHuesosSurgical treatmentAdverse effectChildrenPaediatric foot030222 orthopedicsbusiness.industrySubungual osteochondromaPediatríalcsh:RTumors en els infantsGeneral MedicinePhalanxmedicine.diseasepaediatric footSurgeryExtremitatsPodologíasubungual osteochondromaBone tumourRadiological weaponRight lower limbbusinessCase series
researchProduct

Bridge-Induced Translocation between NUP145 and TOP2 Yeast Genes Models the Genetic Fusion between the Human Orthologs Associated With Acute Myeloid …

2017

In mammalian organisms liquid tumors such as acute myeloid leukemia (AML) are related to spontaneous chromosomal translocations ensuing in gene fusions. We previously developed a system named bridge-induced translocation (BIT) that allows linking together two different chromosomes exploiting the strong endogenous homologous recombination system of the yeast Saccharomyces cerevisiae. The BIT system generates a heterogeneous population of cells with different aneuploidies and severe aberrant phenotypes reminiscent of a cancerogenic transformation. In this work, thanks to a complex pop-out methodology of the marker used for the selection of translocants, we succeeded by BIT technology to preci…

P53bridge-induced translocationgene fusionnucleoporinacute myeloid leukemiayeastlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282Frontiers in Oncology
researchProduct

Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoin…

2021

Gastrointestinal stromal tumors (GISTs) represent 1% of all primary gastrointestinal tumors. Immune surveillance is often overcome by cancer cells due to the activation of immunoregulatory molecules such as programmed death protein (PD-1) and its ligand PD-L1, and butyrophilin sub-family 3A/CD277 receptors (BTN3A). Because several studies demonstrated that tumor PD-1 and PD-L1 expression may have a prominent prognostic function, this investigation aimed to discover if soluble forms of these molecules may be useful in predicting survival of metastatic GIST (mGIST) patients. Through specific ad hoc developed ELISA assays not yet available on the market, the circulating PD-1, PD-L1, BTN3A1, an…

PD-L10301 basic medicineCancer ResearchStromal cellSettore MED/06 - Oncologia MedicaArticle03 medical and health sciencesExon0302 clinical medicineImmune systemButyrophilinPD-L1PD-1Medicineprognostic biomarkerReceptorRC254-282butyrophilinsbiologyGiSTbusiness.industrycirculating immune checkpointsNeoplasms. Tumors. Oncology. Including cancer and carcinogensBTN3A1Antitumor immune response BTN3A1 Butyrophilins Circulating immune checkpoints GIST PD‐1 PD‐L1 Prognostic biomarkerantitumor immune response030104 developmental biologyOncology030220 oncology & carcinogenesisCancer cellCancer researchbiology.proteinbusinessGISTCancers
researchProduct

A “Lymphocyte MicroRNA Signature” as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastat…

2020

Introduction of checkpoint inhibitors resulted in durable responses and improvements in overall survival in advanced RCC patients, but the treatment efficacy is widely variable, and a considerable number of patients are resistant to PD-1/PD-L1 inhibition. This variability of clinical response makes necessary the discovery of predictive biomarkers for patient selection. Previous findings showed that the epigenetic modifications, including an extensive microRNA-mediated regulation of tumor suppressor genes, are key features of RCC. Based on this biological background, we hypothesized that a miRNA expression profile directly identified in the peripheral lymphocytes of the patients before and a…

PD-L10301 basic medicinerenal cell carcinomaCancer Researchmedicine.medical_treatmentLymphocytelcsh:RC254-282Articlepredictive biomarkers03 medical and health sciences0302 clinical medicineRenal cell carcinomaPD-L1PD-1microRNAmedicineEpigeneticsmiRNAmicroRNAbiologybusiness.industrysoluble immune checkpointsImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePredictive biomarker030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchbiology.proteinNivolumabbusinessReprogrammingCancers
researchProduct

PD-1/PD-L1 Checkpoints and Resveratrol: A Controversial New Way for a Therapeutic Strategy

2021

Simple Summary Over the last decade, immunotherapies using antibodies targeting the programmed cell death 1 (PD-1) checkpoint or its ligand, programmed death ligand 1 (PD-L1), have emerged as promising therapeutic strategies against cancer. However, some current limitations include a relatively low rate of “responders”, the high cost of the treatment, and a rare risk of hyper-progression. Currently, the main challenge is, therefore, to improve these therapies, for instance, by using combined approaches. Here, we summarize the accumulating evidence that resveratrol (RSV) plays a role in the modulation of the PD-1/PD-L1 axis in cancer cells, suggesting the potential of therapeutic strategies …

PD-L1Cancer Researchmedicine.medical_treatmentContext (language use)ReviewResveratrolresveratrolchemistry.chemical_compoundImmune systemPD-L1PD-1medicinepolyphenolsRC254-282biologybusiness.industryCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapymedicine.diseaseOncologychemistryCancer cellbiology.proteinCancer researchimmunotherapybusinessAdjuvantCancers
researchProduct

Immune Contexture of MMR-Proficient Primary Colorectal Cancer and Matched Liver and Lung Metastases

2021

Simple Summary Metastasis is the main cause for cancer mortality. The most common metastatic sites of colorectal cancer (CRC) are the liver and lungs. Tumour-infiltrating lymphocytes are recognized as beneficial prognostic factors both in primary and metastatic CRC, but less is known about their reciprocal differences. The aim of our study was to evaluate immune microenvironment and its prognostic value in a series of mismatch proficient (pMMR) CRC with matched liver and lung metastases. The proportion of tumours with high immune cell infiltration together with PD-L1-positivity almost doubled in metastases compared to primary tumours. Our study confirmed the prognostic value of high ICS in …

PD-L1kasvaimet3122 Cancerscolorectal cancersuolistosyövätlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3126 Surgery anesthesiology intensive care radiologylcsh:RC254-282Articleetäpesäkkeettumour infiltrating lymphocytesimmuunivastePD-1lymfosyytitmetastases
researchProduct